{"id":"l-dep-and-pd-1-antibody","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL5095359","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The PD-1 antibody component blocks the programmed death-1 checkpoint, releasing T-cell exhaustion and restoring anti-tumor immune responses. L-DEP (likely a derivative or immunomodulatory agent) works synergistically to enhance immune activation and tumor recognition. This combination approach aims to improve efficacy in checkpoint-resistant or difficult-to-treat malignancies.","oneSentence":"L-DEP and PD-1 antibody is a combination therapy that enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while L-DEP provides immunomodulatory support.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:18:01.023Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT05775705","phase":"PHASE3","title":"L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2023-08-01","conditions":"PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus","enrollment":25},{"nctId":"NCT05315336","phase":"PHASE3","title":"L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2022-06-01","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"L-DEP and PD-1 antibody","genericName":"L-DEP and PD-1 antibody","companyName":"Beijing Friendship Hospital","companyId":"beijing-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-DEP and PD-1 antibody is a combination therapy that enhances anti-tumor immunity by blocking PD-1 checkpoint inhibition while L-DEP provides immunomodulatory support. Used for Advanced or metastatic solid tumors (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}